AgeX & Juvenescence closer to universal allogeneic cells

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

AgeX and Juvenescence publish progress in development of hypoimmunogenic cells.

Longevity focused life sciences companies, AgeX Therapeutics [1] and Juvenescence [2], today announced the publication of a new paper that shows encouraging progress in the development of hypoimmunogenic (or universal) allogeneic cells.

Cell therapy either uses a patient’s own cells (autologous) or donor cells (allogeneic). An allogeneic approach is superior in almost every way, including quality, scalability, manufacturing cost, commercialisation and more. But the biggest challenge facing allogeneic therapy is rejection due to a patient’s immune system response to donor cells. Hypoimmunogenic cells evade a host’s immune system, so engineering allogeneic cells to be universal would be transformative for regenerative medicine.

Today’s paper, published in Regenerative Medicine [3], explores the strategies associated with generation of universal allogeneic cells, and also includes recently published experimental data relating to AgeX’s proprietary immunotolerance technology, UniverCyte [4]. UniverCyte aims to utilise a proprietary, novel, modified form of immunomodulatory molecule HLA-G to generate universal allogeneic cells to enable off-the-shelf therapeutics without the need for immunosuppressants.

The data provides support for the premise that UniverCyte-expressing tissue is potentially hypoimmunogenic and might have escaped recognition by a functional human immune system and continued to grow.

The paper’s lead author is Dr Nafees Malik, Chief Operating Officer at AgeX and Head of Cell & Gene Therapy at Juvenescence.

“Hypoimmunogenic allogeneic cells are the Holy Grail in regenerative medicine, and a number of accomplished researchers have made great strides toward engineering them over the last few years,” said Dr Malik. “This is a huge area of focus for us at AgeX, via our UniverCyte technology platform. In support of our own research and as a service to the overall field, we decided to put together this paper, analyzing all the leading strategies to engineer universal cells and encapsulating them in one paper.”

Co-author Jim Mellon, Chairman of Juvenescence, said, “AgeX’s UniverCyte technology platform will not only be important to the company in developing in-house therapies, it may also be transformative for the wider cell therapy industry via collaborations and licensing deals. It is quite conceivable that in the near future, allogeneic cell therapies may potentially need to be universal to be clinically and commercially competitive.”

AgeX is developing its UniverCyte technology platform at its new 15,700-square-feet R&D facility, in the San Francisco Bay Area.

Co-author Gregory Bailey, MD, Chairman of the Board of Directors of AgeX and CEO of Juvenescence, said, “Universal cells would help us and others to fulfill the original vision of cell therapy. Thus, I am pleased that my colleagues at AgeX and Juvenescence have put together this paper, as it should be of considerable benefit to researchers, possibly enabling them to accelerate their progress.”

Dr Bailey added, “AgeX’s UniverCyte technology uses a novel, modified form of the tolerogenic molecule HLA-G, which in nature plays a key role in preventing a mother from rejecting her semi-allogeneic baby.”

[1] http://www.agexinc.com/
[2] https://juvenescence.ltd/
[3] https://www.futuremedicine.com/doi/10.2217/rme-2019-0117
[4] https://www.agexinc.com/technology/#UniverCyte

 

 

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Printers that can now print DNA

DNA Script obtains CE Mark for SYNTAX DNA printing platform. DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Young blood: discover the possibilities of plasma based therapy

The evolution of plasma-based therapeutics is accelerating – our FREE report cuts through the young blood hype for the lowdown on the latest therapies. Our...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

    Subscribe to our newsletter